Send Inquiry

Request To Call Back

Eltromag Eltrombopag 50mg Tablets

Name: Eltromag Eltrombopag 50mg Tablets
Brand: Truvalis Healthcare
Price: 877.0 INR
Availability: InStock

Price 877.0 INR/ Box

Get a Price/Quote

MOQ : 20 Boxes

Eltromag Eltrombopag 50mg Tablets Specification

Packaging Type
Box

Salt Composition
Eltrombopag Olamine 50 mg

Brand Name
Eltromag

Pacakaging (Quantity Per Box)
7 or 14 tablets per box

Dosage Form
Film-coated tablet

Life Span
36 months (from manufacture date)

Origin of Medicine
India

Indication
Chronic immune thrombocytopenia, aplastic anemia, chronic hepatitis C-associated thrombocytopenia

Drug Type
Other

Ingredients
Eltrombopag Olamine

Physical Form
Other

Function
Other

Recommended For
Treatment of idiopathic thrombocytopenic purpura (ITP) and hepatitis C virus (HCV) infections.

Dosage
As directed by physician

Dosage Guidelines
Once daily or as prescribed by the healthcare provider

Suitable For
Adults

Quantity
10 Unit

Storage Instructions
Store in a cool, dry place below 30C and protect from light

Batch/Lot Number
Information provided on pack

Contraindications
Hypersensitivity to Eltrombopag or any excipients

Regulatory Approval
FDA and CDSCO approved for indicated uses

Route of Administration
Oral

Shape
Round

Barcode
Available on packaging

Marketed By
Zydus Cadila

Prescription/Non Prescription
Prescription

Color
Brown

Caution
Keep out of reach of children. Not to be used without medical supervision.

MRP
Available on packaging

Side Effects
Headache, nausea, diarrhea, increased liver enzymes, fatigue

Eltromag Eltrombopag 50mg Tablets Trade Information

Minimum Order Quantity
20 Boxes

Payment Terms
Cash in Advance (CID)

Supply Ability
500 Boxes Per Month

Delivery Time
7 Days

Main Domestic Market
All India

About Eltromag Eltrombopag 50mg Tablets

Eltromag 50 mg Tablet contains Eltrombopag 50 mg, a thrombopoietin receptor agonist used to increase platelet counts in patients with specific hematological disorders. It is indicated for the treatment of chronic immune thrombocytopenia (ITP), thrombocytopenia associated with chronic hepatitis C infection, and severe aplastic anemia. Eltromag works by stimulating the bone marrow to produce more platelets, helping reduce the risk of bleeding.

Manufactured by Cipla Limited, Eltromag is widely used under specialist supervision in hematology and oncology practice.

Discover the exquisite new release-Eltromag Eltrombopag 50mg Tablets-marketed by Zydus Cadila. Packaged in a gorgeous, decorated box and available in round, brown film-coated tablets, this FDA and CDSCO-approved hematopoietic agent is designed to increase platelet production for individuals with chronic immune thrombocytopenia, aplastic anemia, or hepatitis C-associated thrombocytopenia. Order today and experience a superior treatment process with each 50mg tablet, prescribed by your healthcare provider. Offer available for prescription use only. Caution: Use under medical supervision.

Application Usage and Suitability

Eltromag Eltrombopag 50mg Tablets are specifically designed for adult patients requiring an increase in platelet production due to chronic immune thrombocytopenia, aplastic anemia, or hepatitis C-related thrombocytopenia. Application is exclusively for human medicinal use via the oral route and is not meant for plant, surface or environmental application. To maximize effectiveness, Eltromag should only be used as prescribed, ensuring each surface-in this case, the gastrointestinal tract-receives the intended therapeutic benefit.

Shipment, Packaging, and Exchange Process

Shipment of Eltromag Eltrombopag 50mg Tablets originates from India, with FOB port options on demand. Efficient packaging ensures product integrity during exchange and shipment, with batch and barcode details clearly available on each box. Payment terms are flexible, supporting advance, wire transfer, or as agreed upon order. Expect prompt delivery, with shipment timelines customized to your location. Each box contains either 7 or 14 tablets, ensuring convenience and reliability throughout the exchange process.

We support international procurement requirements for:

Pharmaceutical importers and distributors
Hospitals and specialty clinics
Hematology and oncology centers
Government procurement agencies
NGOs and humanitarian healthcare programs
International healthcare suppliers

FAQ's of Eltromag Eltrombopag 50mg Tablets:

Q: How should Eltromag Eltrombopag 50mg Tablets be administered?

A: Eltromag Eltrombopag 50mg Tablets are administered orally, once daily, or as directed by your healthcare provider. It is important to follow the prescribed dosage and timing to ensure optimal therapeutic benefit.

Q: What are the main indications for using Eltromag Eltrombopag 50mg Tablets?

A: The tablets are indicated for increasing platelet production in adults with chronic immune thrombocytopenic purpura (ITP), aplastic anemia, and chronic hepatitis C-associated thrombocytopenia.

Q: When should Eltromag Eltrombopag 50mg Tablets not be used?

A: These tablets should not be used if you have hypersensitivity to Eltrombopag or any of its excipients. Always consult a healthcare provider before starting treatment.

Q: Where is Eltromag Eltrombopag 50mg manufactured and who markets it?

A: Eltromag Eltrombopag 50mg Tablets are manufactured in India and marketed by Zydus Cadila, a reputable pharmaceutical exporter, supplier, trader, and wholesaler.

Q: What side effects may occur during the usage of Eltromag Eltrombopag 50mg Tablets?

A: Common side effects include headache, nausea, diarrhea, increased liver enzymes, and fatigue. Consult your healthcare provider if you experience any unusual symptoms.

Q: What benefit does Eltromag Eltrombopag 50mg provide to patients?

A: Eltromag increases platelet production, lowering the risk of bleeding complications in patients with thrombocytopenia, thereby improving overall quality of life under medical supervision.

Q: Can you supply Eltromag for export?

A: Yes. We support export inquiries from licensed pharmaceutical importers, distributors, hospitals, NGOs, and healthcare institutions, subject to local regulations and product availability.